Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2020 May 7.
Published in final edited form as: Hemoglobin. 2019 May 7;43(1):42–49. doi: 10.1080/03630269.2019.1597731

Insights into the Progression of Labile Hb A1c to Stable Hb A1c via a Mechanistic Assessment of 2,3-Bisphosphoglycerate Facilitation of the Slow Nonenzymatic Glycation Process

Christina R Mottishaw a, Stephanie Becker a, Brandy Smith a,c, Gentry Titus b, RW Holman a, Kenneth J Rodnick c
PMCID: PMC7196372  NIHMSID: NIHMS1572148  PMID: 31060394

Abstract

Nonenzymatic glycation (NEG) of human hemoglobin (Hb A) consists of initial non covalent, reversible steps involving glucose and amino acid residues, which may also involve effector reagent(s) in the formation of labile Hb A1c (the conjugate acid of the Schiff base). Labile Hb A1c can then undergo slow, largely irreversible, formation of stable Hb A1c (the Amadori product). Stable Hb A1c is measured to assess diabetic progression after labile Hb A1c removal. This study aimed to increase the understanding of the distinctions between labile and stable Hb A1c from a mechanistic perspective in the presence of 2,3-bisphosphoglycerate (2,3-BPG). 2,3-Bisphosphoglycerate is an effector reagent that reversibly binds in the Hb A1c pocket and modestly enhances overall NEG rate. The deprotonation of C2 on labile Hb A1c in the formation of the Amadori product was previously proposed to be rate-limiting. Computational chemistry was used here to identify the mechanism(s) by which 2,3-BPG facilitates the deprotonation of C2 on labile Hb A1c. 2,3-Bisphosphoglycerate is capable of abstracting protons on C2 and the α-nitrogen of labile Hb A1c and can also deprotonate water and/or amino acid residues, therefore preparing these secondary reagents to deprotonate labile Hb A1c. Parallel reactions not leading to an Amadori product were found that include formation of the neutral Schiff base, dissociation of glucose from the protein, and cyclic glycosylamine formation. These heretofore under appreciated parallel reactions may help explain both the selective removal of labile from stable Hb A1c and the slow rate of NEG.

Keywords: Amadori product; conjugate acid of Schiff base; Hb A1c; 2,3-bisphosphoglycerate (2,3-BPG); nonenzymatic glycation (NEG); water

Introduction

The covalent attachment of glucose to proteins is a well-known posttranslational modification that proceeds via a slow process called nonenzymatic glycation (NEG) [13]. The most clinically-relevant model protein for the study of the NEG process in vivo is human hemoglobin (Hb A) [1]. The initial stage of the NEG process (Figure 1) is the noncovalent binding of a glucopyranose ring (structure 1), which then ring opens, while bound to protein, to a more reactive ring-opened aldehydic form of glucose (structure 2), that is still non covalently bound [4]. After several mechanistic steps, (structure 2) can proceed to a covalently-attached conjugate acid of the Schiff base (structure 3). Specifically, when the conjugate acid of the Schiff base (structure 3) is formed at one (or both) of the N-terminal Val1 residues on the two β chains of the Hb A tetramer [5,6], the resulting species is clinically referred to as labile Hb A1c or pre Hb A1c. Labile Hb A1c (structure 3) can then proceed via multiple mechanistic steps to generate a covalently-attached Amadori product (structure 6), clinically referred to as Hb A1c or stable Hb A1c [7,8]. Stable Hb A1c can then proceed via multiple mechanistic steps to an array of advanced glycation end (AGE) products [9].

Figure 1.

Figure 1.

The five fates of labile Hb A1c, structure 3, the conjugate acid of a Schiff base (located in the rectangle in the middle of the figure) that is generated in the NEG process for glucose in the Val1 pocket of Hb A in the presence of 2,3-BPG. Note that the relative lengths of arrows on reversible steps for all the mechanistic pathways (except mechanistic pathway I) are drawn with equal length. This does not suggest that the equilibrium in both directions is equal. Rather, the degree of forward vs. reverse equilibrium varies with conditions and thus are rendered in the figure without respect to the relative magnitude of the equilibrium. For mechanistic pathway I, the reverse process out-competes the forward process under all conditions. In the noncovalent stages of NEG, a glucopyranose molecule structure 1, must first enter the Hb A1c protein pocket and then be modified to ring-opened species structure 2 while in the pocket, so it can become sufficiently reactive [4]. Structure 2 can then undergo multiple reactions to covalently bond to the N-terminal valine and become structure 3, the conjugate acid of the Schiff base which is labile Hb A1c [26]. Mechanistic pathway I: in structure 3 (labile Hb A1c), the asterisk (*) denotes the C2 atom. The proton on the C2 atom is blue and, in this study, is referred to as the C2 proton. The C2 proton can be deprotonated by a base, specifically the lone pair of electrons on the oxygen of a phosphate or a lone pair of electrons on the oxygen of the carboxylate of tetraanionic 2,3-BPG. This reversibly generates structure 5, which, by multiple steps (not shown), can then irreversibly go to structure 6, stable Hb A1c. This pathway is referred to as ‘C2 deprotonation’ in Table 1 and constitutes the direct formation of Hb A1c. Mechanistic pathway II: in structure 3, (labile Hb A1c), the green proton on the nitrogen is abstracted by a base. The abstraction generates structure 3a. Note that structure structure 3a is what has been mistakenly referred to in many other articles as labile Hb A1c. Structure 3a has no direct connection to structure 6, stable Hb A1c, without firstly reverting back to structure 3. This pathway referred to as ‘N deprotonation’ in Table 1. Mechanistic pathway III: here a nucleophilic water molecule (not shown in the figure) attacks the C1 carbon of structure 3, and, after multiple mechanistic steps (not shown), the result is reversion to structure 2, that is noncovalently-bound in the protein pocket, which then can go to structure 1. This constitutes a complete detachment of structure 1 (ring-closed glucose) from Hb A. This is referred to as ‘H2O nucleophilic attack’. Note that 2,3-BPG is not necessarily involved in this mechanistic pathway. However, 2,3-BPG can potentially facilitate H2O nucleophilicity, which would mean that 2,3-BPG can inhibit Hb A1c formation by this pathway. Mechanistic pathways IV and V: both pathways IV and V involve the electrophilic C1 of structure 3 (designated with a ^) undergoing an intramolecular nucleophilic attack by a lone pair of electrons on an oxygen atom of an OH on either C5 (generating structure 4a) or C4 (generating structure 4b). Neither structure 4a or 4b has a direct connection to structure 6, stable Hb A1c, without first reverting back to structure 3. These mechanistic pathways are referred to collectively as ‘intramolecular OH nucleophilic attack’.

The overall NEG process results in covalent modification of Hb A by glucose (referred to as glycation). The specific structures for covalently-modified Hb A are a composite of structures 3 (formed reversibly), 4a, 4b and 6 (formed with modest reversibility), and AGE (formed non reversibly). Covalent modification of a protein by glucose can alter protein function [10] and is thought to be linked to the chronic complications of diabetes mellitus [11]. This glucose concentration-dependent process is accelerated in diabetic patients due to persistent hyperglycemia.

The clinical measurement of stable Hb A1c (structure 6), reflects average glycemia and the continuous process of NEG occurring over approximately 3 months and highlights the slow time frame for the glycation of intracellular proteins [1,2,4,12] compared to enzymatic processes. Stable Hb A1c also has a strong predictive value for microvascular complications and cardiovascular disease in populations with diabetes [11]. A key initial step in the measurement of stable Hb A1c (structure 6) is the elimination its precursor, labile Hb A1c (the conjugate acid of the Schiff base, structure 3) in vitro [13]. However, recent studies by Hempe et al. [14] suggest that labile Hb A1c is not a single chemical structure but consists of multiple structures with interrelated dissociation kinetics. It is also apparent that multiple effector reagents may facilitate the formation of structure 6 in vivo.

An effector reagent is a small molecule that can concomitantly bind and thus reside in the same protein pocket with a glucopyranose. Effector reagents can either facilitate or inhibit covalent bond making or bond breaking [15]. The organic phosphate 2,3-bisphosphoglycerate (2,3-BPG) is a physiological species that can be an effector reagent. 2,3-Bisphosphoglycerate exists as a mixture of multiple anionic forms in a pH-dependent dynamic equilibrium. The major organic phosphate in human erythrocytes is 2,3-BPG, and, at a normal concentration of 4.0–5.0 mM, is comparable to Hb A on a molar basis [16]. 2,3-Bisphosphoglycerate is known to bind in the N-terminal Val1 pocket between the β chains of Hb A [17]. 2,3-Bisphosphoglycerate is also thought to accelerate Hb A glycation modestly in the conversion of structure 3 (labile Hb A1c) to the Amadori product (structure 6) (stable Hb A1c) [12]. Specifically, under aerobic and anaerobic conditions, the rate of Hb A1c formation in vitro was 30.0 and 50.0% higher, respectively, at high (~9.0 mM) vs. low (0.7–0.8 mM) 2,3-BPG concentrations in human erythrocytes.

The focal point of the current study is framed around three interrelated questions. First, can a more complete understanding of why the overall NEG process is relatively slow arise from a mechanistic analysis of the interplay between labile- and stable-Hb A1c? Second, how do the clinical assay methods utilized for removing labile Hb A1c work and what are the chemical structures and mechanistic pathways involved? Finally, how is 2,3-BPG involved in the interplay between labile- and stable-Hb A1c? Computational methods were employed to follow the progression from labile Hb A1c formation to the generation of stable Hb A1c. Specific emphasis was placed on chemical bond making/bond breaking participation by 2,3-BPG in this transformation. In addition, an assessment of possible parallel mechanistic pathways (here defined as reactions) that do not directly proceed from labile-to-stable Hb A1c, was developed and discussed in relation to the NEG process. This study is intended to contribute to a more accurate and complete depiction of the NEG process that produces stable Hb A1c.

Materials and methods

A fully oxygenated Hb A crystal tetramer PDB 1GZX, a partially oxygenated PDB 1B86 Hb A tetramer with tetrabasic 2,3-BPG bound, and a fully deoxygenated Hb A crystal tetramer PDB 1BZ0 were utilized (from http://www.rcsb.org/). Both dianionic and tetraanionic 2,3-BPG structures were generated from a tetraanionic 2,3-BPG structure (RCSB PDB) and energy minimized within molecular operating environment (MOE, 2013.08; Chemical Computing Group ULC, Montreal, Québec Province, Canada). Both forms of 2,3-BPG were utilized because the intrinsic pKa values for protons associated with the phosphate groups bound to C2 and C3 of 2,3-BPG are 6.99 and 7.28, respectively [18], meaning that both dianionic and tetraanionic 2,3-BPG will be physiologically present. Starting from the original RCSB PDB crystal structure, the N-terminal Val1 of the β chains was modified to a conjugate acid of the Schiff base (structure 3) and geometry minimized in MOE (computational modification of geometry to arrive at the minimal energy structure conformation). Further modification of RCSB PDB crystal structures included protonation or deprotonation of specific amino acid residues followed by geometry optimization to generate proteins in different charge states. Specifically, each Hb A structure was modified within MOE such that one N-terminal Val1 was modified to the conjugate acid of the Schiff base and the other was either a nucleophilic NH2 amine or a NH3+ ammonium cation. All lysine R groups of the Hb A tetramer were ammonium cations (NH3+). Histidine R groups were R-N neutral species and aspartic acid and glutamic acid R groups were R-COO anion species. Water was already present within all the crystal structures analyzed.

Single effector reagents (2,3-BPG or water) were then placed in the Val1 pocket between the β chains of 1BZ0 and 1GZX (whether modified or not) and geometry optimized. The energy-minimized structures were then visualized and evaluated for potential mechanisms. A conservative cutoff distance of 5Å between potential reactive centers (distances between acidic protons and basic lone pairs of electrons; distances between nucleophilic and electrophilic atoms, etc.) was employed [19,20]. The reactive centers considered included reactive atoms (or lone pairs of electrons) on effector reagents (non covalently bound 2,3-BPG and/or water), the non covalently bound glucose, and resident amino acids in the Val1 pocket. From these measurements, potential mechanistic pathways were identified. Mechanistic pathways that involved deprotonation of the C2 structure 3 (Figure 1) in forward progression to the Amadori product (structure 6) were considered. In addition, all potential mechanistic pathways from structure 3 whether they led to structure 6 or not, were assessed.

Results

Table 1 lists the species involved in geometrically-possible reactions of labile Hb A1c [which is the conjugate acid of the Schiff base (structure 3) in the Hb A1c pocket] both without and with 2,3-BPG present. For crystals without 2,3-BPG pre bound (1BZ0 and 1GZX), the neighboring His2 residue was the only residue within the 5Å cutoff distance that could serve as a potential base towards the C2 hydrogen of structure 3. This reaction is designated as ‘C2 deprotonation’ (Table 1, column 1) and is shown as mechanistic pathway A in Figure 2. The proper geometry for this reaction was achieved in only 12.5% of the conformations observed as energetic minima (Table 1, column 6). Other amino acids (e.g. Lys8, Asp79 and Lys82 on the same β chain) were all at distances greater than 5Å from the proton of interest on the C2 of structure 3. Thus, in the absence of 2,3-BPG in the Hb A1c pocket, based upon our criteria (5Å or less), His2 is the only amino acid residue capable of C2 deprotonation and formation of the Amadori product structure 6 (stable Hb A1c, Figure 1), albeit such a reaction is predicted to be a low probability event based on geometry optimized structures.

Table 1.

A summary of the computational of geometrically-possible reactions of labile Hb A1c structure 3, without and then with a 2,3-bisphosphoglycerate present in the Hb A1c pocket. The results here are limited to mechanistic pathways I and II.

Without 2,3-BPG
Geometrically-Possible Reactionsa Potential Basesb Species Formedc Direct Progression to Amadorid Proper Geometry Achievede
C2 deprotonation (I)f His2 structures 5 then 6 yes 12.5%
N deprotonation (II)f His2 structure 3a no 25.0%
With 2,3-BPG
Geometrically-Possible Reactionsa Potential Basesb Species Formedc Direct Progression to Amadorid Proper Geometry Achievede
C2 deprotonation (I)g 2,3-BPGh structures 5 then 6 yes 98.0%
C2 deprotonation (I)f,i 2,3-BPGh; H2O structures 5 then 6 yes 98.0%
C2 deprotonation (I)i 2,3-BPGj; H2O structures 5 then 6 yes 98.0%
C2 deprotonation (I)g 2,3-BPGh; H2O; His2 structures 5 then 6 yes 98.0%
N deprotonation (II)g 2,3-BPGh; H2O structure 3a no 95.0%
N deprotonation (II)g 2,3-BPGh; Asp79 structure 3a no 95.0%
N deprotonation (II)f,i 2,3-BPGh; H2O structure 3a no 95.0%
N deprotonation (II)i 2,3-BPGk; H2O structure 3a no 95.0%
N deprotonation (II)g 2,3-BPGh; H2O; His2 structure 3a no 95.0%
N deprotonation (II)i 2,3-BPGl; H2O; His2 structure 3a no 95.0%

2,3-BPG: 2,3-bisphosphoglycerate.

a

The geometrically possible reaction designated as ‘C deprotonation’ involves the initial abstraction of the hydrogen on the C2 of the protonated Schiff base (structure 3) by a nearby (less than 5Å) base. The designation of ‘N deprotonation’ involves the initial abstraction of the hydrogen on the nitrogen of structure 3 by a nearby base.

b

The listed species are potential bases based upon a distance between the abstracted proton and the lone pair on the indicated species of less than 5Å. All listed amino acid residues were on the same β chain as the Schiff base. Note that for H2O to act as a suitable base, it must be deprotonated by another base such as 2,3-BPG or an amino acid residue as it deprotonates the designated target species. Note that no distinction between the dianionic and tetraanionic forms of 2,3-BPG are made with respect to these measurements.

c

These species are indicated in Figure 1. Structure 3a is a Schiff base deprotonated at the terminal N, structure 5 is an enol, and structure 6 is an Amadori product.

d

Yes means that direct forward progress to Amadori product structure 4 (and hence, formation of Hb A1c and AGEs) is possible. A No means the indicated structure (2 or 3a) must revert (via reversible reaction) back to the protonated Schiff base structure 3 to then go on to structure 5 and ultimately to structure 6 in the formation of Hb A1c.

e

The percentages listed indicate the percentage of conformations that were calculated as geometry-optimized minima that meet the criteria for potential reaction (e.g. those that meet the less than 5Å distance between reaction centers for the mechanism to occur) vs. the total number of conformations calculated as geometry-optimized minima.

f

Starting PDB crystal:1BZ0.

g

Starting PDB crystal: 1B86.

h

2,3-BPG phosphate groups only.

i

2,3-BPG phosphate groups and carboxyl group.

j

Starting PDB crystal: 1GZX.

k

2,3-BPG phosphate group 1.

l

2,3-BPG phosphate group 2.

Figure 2.

Figure 2.

A representation of four energetic minima calculated from MOE depicting geometrically-possible abstractions of the C2 proton from structure 3 in the Hb A1c pocket under certain conditions. Each is rendered as a partial mechanism, just showing the initial abstraction, and are thus given forward arrows only (though the overall processes are reversible). In the figure BPG represents 2,3-bisphosphoglycerate.

It is noteworthy that for the few structures that are energetic minima where the C2 of structure 3 can be deprotonated by His2 it is also possible to deprotonate the α-nitrogen of structure 3 (which is an ammonium ion). When the α-nitrogen of structure 3 is deprotonated, the neutral Schiff base structure 3a is formed (Table 1, row 2; Figure 1, mechanistic pathway II). This option is possible because the α-nitrogen of structure 3 is just 2.5Å from C2. This reaction is designated ‘N-deprotonation’ (Table 1, column 1). Proper geometry for this reaction occurred in 25.0% of the energy-minimized confirmations. When N-deprotonation occurs, no direct progression to stable Hb A1c is possible.

A summary of the possible fates of the conjugate acid of the Schiff base structure 3 in the Val1 pocket of Hb A in the presence of 2,3-BPG is provided in Figure 1. Starting at the conjugate acid of the Schiff base, structure 3 (Figure 1), formation of the stable Amadori product structure 6 at Val1 of the β chains of Hb A requires the deprotonation of the C2 on structure 3 (Figure 1, mechanistic pathway I; Figure 2, mechanistic pathway B). For any of the energy-minimized crystals containing a bound 2,3-BPG, at least one of the basic groups (one carboxylate and/or one or more of the phosphates of either tetraanionic or dianionic 2,3-BPG) was within reacting distance (~2–5Å) to deprotonate C2 of structure 3. Therefore, Amadori formation via structure 5, and then structure 6 (Figure 1, mechanistic pathway I and Table 1, with 2,3-BPG, row 1) is geometrically possible. Proper geometry for this reaction was achieved in essentially all (98.0%) of the conformations observed as energetic minima.

In addition, 2,3-BPG can function indirectly by deprotonating nearby water and/or native amino acid residues, preparing these secondary reagents to deprotonate the conjugate acid of the Schiff base structure 3 (Figure 2, mechanistic pathway C). Therefore, a computational investigation of the degree of potential water and amino acid residue participation was conducted. In the Hb A1c pocket in the absence of 2,3-BPG, water was present but was not in range (5Å) to deprotonate the C2. Thus, water participation in the absence of 2,3-BPG is unlikely. In pockets with 2,3-BPG present, there were anywhere from 1–6 water molecules within 5Å of the C2 proton that are also within range for 2,3-BPG to facilitate water basicity. Thus, water participation as a secondary species acting as a base facilitated by 2,3-BPG is predicted to occur with high probability (Table 1, with 2,3-BPG, rows 3–10).

Bound 2,3-BPG can facilitate C2 deprotonation in yet another indirect mechanistic pathway. The inclusion of 2,3-BPG in the Hb A1c pocket can change the conformation of the Hb A1c pocket and move certain basic amino acid residues closer to the acidic proton on structure 3. This conformational change, a proximity effect, brings previously unavailable basic amino acid residues (<5Å) close enough to deprotonate the C2 of structure 3 without any direct 2,3-BPG participation (Figure 2, mechanistic pathway D). Specifically, the presence of bound 2,3-BPG induced conformational change such that the basic sites on Asp73, Asp79 and/or His2, were moved to within 5Å of the proton of the C2 of structure 3 (note that none of these amino acid residues were close enough to the C2 proton in pockets without 2,3-BPG present).

The α-nitrogen of structure 3 can also be deprotonated forming the neutral Schiff base structure 3a (Table 1 and Figure 1, mechanistic pathway II). Potential bases in this reaction are 2,3-BPG, Asp79, His2, or water facilitated by 2,3-BPG. This diverse set of reactions falls under the ‘N deprotonation’ designation (Table 1, with 2,3-BPG, rows 10–14). Proper geometry for these reactions occurred in the vast majority (95.0%) of the energy-minimized structures and involved the conjugate acid of the Schiff base on the β1Val1 and β2Val1 of Hb A. Regardless of which basic species is involved in the mechanism, structure 3a is the resulting species generated and has no direct connection to structures 5 or 6 without first reverting back to structure 3 (Figure 1).

Based upon computations from MOE, the reversion from structure 3 to a detached glucose structure 2 and the unmodified βVal1 is geometrically viable (Table 1, second to last row). Reversible formation of cyclic glycosylamines structure 4a (α and β forms of six-membered rings), and structure 4b (α and β forms of five-membered rings) were computationally predicted to occur via pathways IV and V, respectively. The reversible formation of the cyclic glycosylamines does not afford a direct path to structure 6 without first reverting back to structure 3.

Discussion

In landmark early investigations, both Higgins and Bunn [21] and Lowrey et al. [22], established that the formation of labile Hb A1c (which was then referred to as pre-Hb A1c) was reversible and not rate-limiting in the overall NEG process (i.e. formation of labile Hb A1c is a relatively fast step). It should be noted that in most extant schemes in the literature, including [21,22], labile Hb A1c was rendered as a neutral Schiff base (an imine; structure 3a in Figure 1) when, in fact, the initially-formed labile Hb A1c is the conjugate acid of the Schiff base (an iminyl ion). A more complete depiction of labile Hb A1 formation has been forwarded by Clark et al. [4], Rodnick et al. [15] and Park et al. [23], which includes the recently-discovered detail that the initial glucose species that binds to Hb A is not ring-opened but is rather a cyclic glucopyranose that ring-opens while bound as a necessary precondition before it leads to structure 3, the conjugate acid of the Schiff base that is labile Hb A1c. Gil et al. [24] recognized and highlighted that structure 3 is the initially-formed covalent species when a nucleophilic amino acid residue (e.g. the amine form of the N-terminal Val1 on the two β chains of Hb A) reacts with the electrophilic ring-opened form of glucose (structure 2). Moreover, several studies have shown that the rate of structure 3 formation is influenced by effector reagents such as inorganic phosphate and water serving as acids and/or bases [3,20,25,26].

Lowrey et al. [22] suggested and Gil et al. [24] demonstrated that the formation of stable Hb A1c structure 6 from labile Hb A1c structure 3 is largely (or entirely) irreversible and slow, constituting the rate-determining step of NEG for Hb A in the presence of 2,3-BPG. Smith et al. [12], extending from their data, posited that the rate of conversion from the conjugate acid of the Schiff base (labile Hb A1c, structure 3) to stable Hb A1c (structure 6, the Amadori product; Figure 1, mechanistic pathway I) increases under the influence of nearby 2,3-BPG. Gil et al. [24], using kinetic isotope effect (KIE) analysis, definitively demonstrated that the mechanistic step that determines the rate of stable Hb A1c formation in the presence of 2,3-BPG is the abstraction of the C2-proton on structure 3, by a base (Figure 1, mechanistic pathway I, with the abstraction of the proton that is rendered in blue). The KIE method of Gil et al. [24] did not, however, enable the identification of the specific base (or bases) involved. Our intent is to discern what the base(s) is/are that deprotonate the C2 proton on labile Hb A1c structure 3 in the progression towards stable Hb A1c structure 6 and to determine whether other acid/base and/or nucleophile/electrophile reactions can occur that alter the rate of progression from structures 3 to 6. The intent is to elucidate why stable Hb A1c formation is so slow (on the order of weeks) and to better understand the structural/mechanistic chemistry associated with the clinical assay methods utilized to eliminate labile Hb A1c structure 3 prior to the measurement of stable Hb A1c structure 6.

Our computational assessment predicts that His2 is the only amino acid residue capable of C2 deprotonation in the formation of the Amadori product structure 6 (stable Hb A1c, Figure 1) in the absence of 2,3-BPG. This singular mechanistic pathway is predicted to occur with low probability (only 12.5% of the predicted conformations that were energetic minima had suitable geometry to react). Despite the molecular proximity of His2 to the C2 of structure 3 in the Hb A1c pocket, a significant geometric constraint for the reaction exists. This may ultimately help explain the low probability of His2 participation in C2 deprotonation of the conjugate acid of the Schiff base (structure 3). In addition, for all geometric energy minima where the C2 of structure 3 can be deprotonated by His2, the α-nitrogen of structure 3 (an ammonium ion) can also be deprotonated. N-deprotonation of structure 3 is a viable reaction with twice the geometric probability as C2 deprotonation (Table 1). Moreover, the proton on N (Figure 1 rendered in green; pKa ~14) is far more acidic and is therefore much easier to deprotonate than is the proton on C2 (pKa ~20; Figure 1, rendered in blue). Furthermore, N-deprotonation of structure 3 generating structure 3a, has no direct connection to structures 5 or 6 without first reverting back to structure 3. Thus, stable Hb A1c formation in the absence of 2,3-BPG and any other effector reagent should be extremely slow. However, it should be noted from earlier studies that physiological inorganic phosphate (existing at concentrations of 0.5–0.8 mM in the erythrocyte) [27] can bind with glucose in the Hb A1c pocket and serve as an effector reagent, increasing the rate of Hb A glycation [26]. Moreover, it is estimated that 67.0% of all Hb A1c pockets in erythrocytes possess a bound 2,3-BPG [28]. The salient point not highlighted in previous studies is that without an effector reagent, the rate of conversion from structure 3 to structure 6 would be exceedingly slow.

The carboxylate and/or one of the phosphates of either tetraanionic 2,3-BPG or dianionic 2,3-BPG, were close enough (~2–5Å) to directly deprotonate C2 of structure 3 in 98.0% of all energetic minima conformations. Unlike the geometrically-constrained His2 with a single lone pair of electrons on nitrogen capable of serving as a reactive base, 2,3-BPG is less constrained and has as many as five oxygen atoms with lone pairs of electrons that can potentially serve as a base. Furthermore, 2,3-BPG has many more conformations with the requisite geometry to deprotonate the C2 of structure 3 than does His2. In addition, 2,3-BPG can function indirectly by deprotonating nearby water and/or native amino acid residues, preparing these secondary reagents to deprotonate the conjugate acid of the Schiff base structure 3 (Supplementary Figure 1, mechanistic pathway C). The presence of numerous water molecules (with conformational freedom) associated with 2,3-BPG in the Hb A1c pocket and the ability of water to serve as a base when deprotonated by 2,3-BPG highlights another underappreciated potential pathway for 2,3-BPG to deprotonate structure 3 and proceed to structure 6. Bound 2,3-BPG can also facilitate C2 deprotonation in yet another indirect mechanistic pathway. The inclusion of 2,3-BPG in the Hb A1c pocket can change the conformation of the Hb A1c pocket and move the surrounding amino acid residues closer to structure 3 (Supplementary Figure 1, mechanistic pathway D). This conformational change constitutes a proximity effect and brings previously unavailable basic amino acid residues (<5Å) close enough to deprotonate the C2 of structure 3 (without any direct 2,3-BPG participation).

An assessment of the reactive possibilities available to labile HbA1c (structure 3, the conjugate acid of the Schiff base) is key in discerning why NEG is so slow. Five nonenzymatic fates for structure 3 exist. Only mechanistic pathway I produces stable Hb A1c directly. The 2,3-BPG and other potential bases such as His2, Asp79, or water can also directly or indirectly deprotonate the α-nitrogen of structure 3 forming the neutral Schiff base structure 3a, a species that cannot go to stable Hb A1c structure 6 without first returning to structure 3 (Figure 1, mechanistic pathway II). The reversion from structure 3 to a detached glucose structure 3 and the unmodified βVal1 is shown as mechanism pathway III (Figure 1). From this, the glucose can entirely dissociate from the protein and thus this mechanistic pathway equates to reversion to starting species. Lastly, reversible formation of cyclic glycosylamines structure 4a (α and β forms of six-membered rings), and structure 4b (α and β forms of five-membered rings) were computationally predicted to occur via pathways IV and V, respectively (Figure 1).

Mechanistic pathways (II-V) are all reversible pathways and, when manifest, will compete against stable Hb A1c structure 6 formation (Figure 1, mechanistic pathway I). Because there are so many geometrically viable reactions from labile Hb A1c structure 3 that do not proceed to stable Hb A1c structure 6 the formation of structure 6 should be limited. Furthermore, C2 deprotonation is already known to be the rate-limiting step in the formation of stable Hb A1C [24], albeit without mechanistic justification. Given that the only mechanistic pathway that does lead to structure 6 must involve C2 deprotonation (Figure 1), our proposed mechanism supports the original posit that deprotonation of the C2 proton should be rate-limiting. It is important to note that the degree of reversibility for these competing equilibria are unknown.

A common procedure utilized to eliminate labile Hb A1c structure 3 from the clinical assay of stable Hb A1c structure 6, is to add acid to a pH of ca. 5–6 [29]. How is this method efficacious for the selective removal of structure 3? When acid is added, both the deprotonation of the C2 proton and the proton on the nitrogen of structure 3 is disfavored, thus mechanistic pathways I and II (Figure 1) become less competitive. Because mechanistic pathway I is the only path from labile Hb A1c structure 3 to stable Hb A1c structure 6 and this pathway becomes less competitive with acid addition, little (or perhaps none) of the structure 3 that exists in a blood sample will proceed to structure 6. The only outlet that is productive (that leads to something other than the reversible formation of structure 3) will be mechanistic pathway III (Figure 1) that will lead, ultimately, to the detachment of a glucose molecule from the Hb A protein [for the mechanism for this process, see Supplementary Figure 1(a)]. At the same time that structure 3 is depleted upon acid addition (exiting as glucose), any stable Hb A1c structure 6 present in the clinical mixture will react with acid and merely undergo reversible protonation/deprotonation [for the mechanism for this process, see Supplementary Figure 1(b)] that cannot detach the glucose from the protein. Thus, acid addition to a mixture of structures 3 and 6 will selectively eliminate the labile Hb A1c structure 3 (as detached glucose) from the stable Hb A1c structure 6, while stable Hb A1c structure 6 concentration will be unaffected. This mechanistic extrapolation provides a plausible explanation for why the addition of acid to a blood sample will enable an accurate measurement of stable Hb A1c structure 6 free of labile Hb A1c structure 3.

A second clinical laboratory method for the removal of labile from stabile Hb A1c involves the addition of phosphate at a high concentration [13]. This methodology may be explained by the Le Chatelier and Braun principle [30], which states that if a reactant’s concentration is decreased in a dynamic reversible equilibrium, the equilibrium will shift to the left (towards starting materials). Our computational data predicts that as phosphate is added, it binds HbA in competition with a glucopyranose [26]. In some clinical assays of stable Hb A1c, phosphate has been added to hemolyzing solutions at levels well above physiological values (e.g. 100 mM [31]), which should therefore reduce the effective concentration of glucopyranose. This procedure will shift the equilibrium in mechanistic pathway III (Figure 1) toward detached glucose, likely resulting in the removal of structure 3 from the Hb A1c pocket. The addition of phosphate will not affect the concentration of structure 6, because the formation of structure 6 is largely irreversible and thus, for structure 6, the Le Chatelier and Braun principle [30] is not operative. As such, addition of phosphate to a mixture of structures 3 and 6 will likely slowly remove the labile Hb A1c structure 3 (as detached glucose) without affecting the concentration of stable Hb A1c structure 6, enabling an accurate measure of stable Hb A1c structure 6 free of complicating structure 3. A related strategy to remove labile Hb A1c from blood samples is the lowering of the concentration of extracellular glucose [13]. Once again, depending on the incubation temperature, glucose concentration, and time, the Le Chatelier and Braun principle [30] will likely be operative and selective for the elimination of labile Hb A1c prior to clinical assays of stable Hb A1c.

In summary, starting from labile Hb A1c structure 3, mechanistic pathways II, III, IV and V are all computationally viable and yet do not lead directly to stable Hb A1c, structure 6. The only direct path from labile Hb A1c, structure 3, to stable Hb A1c, structure 6 is mechanistic pathway I. Thus, with respect to the formation of structure 6, mechanistic pathways II, III, IV and V are unproductive and occur in competition with stable Hb A1c formation. Therefore, as the extent of II, III, IV and/or V increases relative to I, the amount of stable Hb A1c, structure 6 formation is reduced. These multiple unproductive fates for labile Hb A1c, structure 3 formed in the NEG of human Hb A have not been reported before and are the likely reason for the slow overall progression of NEG. The addition of 2,3-BPG increases the rate of both structures 3 and 6 formation (via mechanistic pathway I). Finally, the described mechanistic pathways and effects of the Le Chatelier and Braun principle [30] can help explain how the successful strategies to selectively remove labile Hb A1c structure 3 from clinical laboratory assays of stable Hb A1c structure 6 studies.

Supplementary Material

Supp1

Supplementary Figure 1. Impacts of added acid on a mixture of labile and stable Hb A1c. The first section of Figure (a): labile Hb A1c outlines the result of adding excess acid (H-A+) to labile Hb A1c. First, a nearby water molecule must attack as a nucleophile at the electrophilic C double bonded to the N. Then, a base (B that can be 2,3-BPG, water, etc.) abstracts the proton from the now-attached water molecule to form the uncharged carbinolamine species. The carbionolamine is then protonated by an acid (H-A+), which is now a sufficiently reactive species. This is the key step at which added acid promotes the removal of labile Hb A1c, structure 3, by facilitating the protonation of the carbinolamine that then undergoes an intramolecular rearrangement, where one lone pair of electrons on the O forms a double bond with the neighboring C as the bond between the N and the C is broken. The products of this reaction are a ring-opened glucose (structure 2) and the native amino acid residue (either a lysine or the N-terminal valine). Structure 2 can then undergo an intramolecular reaction to form the species shown above, a ring-closed glucopyranose (structure 1), or any of the glucose anomers and tautomers. The newly reformed glucose species can then disassociate entirely from the protein pocket and return to solution, leaving a pocket without any process in NEG. Therefore, addition of acid to labile Hb A1c results in reversion of NEG and does not form AGEs. The second section of Figure (b): stable Hb A1c outlines the result of adding excess acid (H-A+) to structure 6 stable Hb A1c. Two different reactions can occur. The first, colored in dark green and labeled a, involves the deprotonation of an acidic species by the α-nitrogen. The product, an N-protonated Amadori intermediate has no outlet other than to return to structure 6. The second reaction is colored in bright blue and is labeled b. The product, an O-protonated Amadori intermediate has no outlet other than to return to structure 6. It is important to note that there is no reversion to labile Hb A1c or to the ring-opened glucose with the addition of acid. The glucose has no chance to disassociate from the protein, and thus, both reactions have no productive outlet, and can only return to structure 6. Therefore, addition of acid to stable Hb A1c does not affect the concentration of structure 6 or the degree of AGE formation. Taken collectively then, addition of acid will remove labile Hb A1c, structure 3, by pushing the equilibrium towards the formation of detached glucose while the concentration of stable Hb A1c structure 6, remains constant.

Acknowledgments

Funding

This study was supported by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences [grant number P20GM103408]. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Institutes of Health, Bethesda, MD, USA. Further support was provided by the Departments of Biological Sciences and Chemistry and the College of Science and Engineering at Idaho State University, Pocatello, ID, USA.

Footnotes

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

References

  • [1].Bunn HF, Gabbay KH, Gallop PM. The glycosylation of hemoglobin: relevance to diabetes mellitus. Science. 1978;200(4337):21–27. [DOI] [PubMed] [Google Scholar]
  • [2].Stevens VJ, Vlassara H, Abati A, et al. Nonenzymatic glycosylation of hemoglobin. J Biol Chem. 1977;252(9):2998–3002. [PubMed] [Google Scholar]
  • [3].Watkins NG, Neglia-Fisher CI, Dyer DG, et al. Effect of phosphate on kinetics and specificity of glycation of protein. J Biol Chem. 1987;262(15):7207–7212. [PubMed] [Google Scholar]
  • [4].Clark SLD, Santin AE, Bryant PA, et al. The initial noncovalent binding of glucose to human hemoglobin in nonenzymatic glycation. Glycobiology. 2013;23(11):1250–1259. [DOI] [PubMed] [Google Scholar]
  • [5].Bookchin RM, Gallop PM. Structure of hemoglobin A1c: nature of the N-terminal β chain blocking group. Biochem Biophys Res Commun. 1968;32(1):86–93. [DOI] [PubMed] [Google Scholar]
  • [6].Little RR, Sacks DB. HbA1c: how do we measure it and what does it mean? Curr Opin Endocrinol. 2009;16(2):113–118. [DOI] [PubMed] [Google Scholar]
  • [7].Bunn HF. Evaluation of glycosylated hemoglobin in diabetic patients. Diabetes. 1981;30(7):613–617. [DOI] [PubMed] [Google Scholar]
  • [8].Gould BJ, Davie SJ, Yudkin JS. Investigation of the mechanism underlying the variability of glycated haemoglobin in non-diabetic subjects not related to glycaemia. Clin Chim Acta. 1997;260(1):49–64. [DOI] [PubMed] [Google Scholar]
  • [9].Brownlee M Advanced protein glycosylation in diabetes and aging. Ann Rev Med. 1995;46(1):223–234. [DOI] [PubMed] [Google Scholar]
  • [10].Rondeau P, Bourdon E. The glycation of albumin: structural and functional impacts. Biochimie. 2011;93(4):645–658. [DOI] [PubMed] [Google Scholar]
  • [11].Forbes JM, Cooper ME. Mechanisms of diabetic complications. Physiol Rev. 2013;93(1):137–188. [DOI] [PubMed] [Google Scholar]
  • [12].Smith RJ, Koening RJ, Binnerts A, et al. Regulation of Hemoglobin A1c formation in human erythrocytes in vitro. Effects of physiological factors other than glucose. J Clin Invest. 1982;69(5):1164–1168. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [13].Furth AJ. Methods of assaying nonenzymatic glycation. Anal Biochem. 1988;175(2):347–360. [DOI] [PubMed] [Google Scholar]
  • [14].Hempe JM, McGehee AM, Hsia D, et al. Characterization of unstable Hemoglobin A1c complexes by dynamic capillary isoelectric focusing. Anal Biochem. 2012;424(2):149–155. [DOI] [PubMed] [Google Scholar]
  • [15].Rodnick KJ, Holman RW, Ropski PS, et al. A perspective on reagent diversity and noncovalent binding of reactive carbonyl species (RCS) and effector reagents in non-enzymatic glycation (NEG): mechanistic considerations and implications for future research. Front Chem. 2017;5(article 39):1–8. doi: 10.3389/fchem.2017.00039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [16].Bishop C, Surgenor DM. The Red Blood Cell: A Comprehensive Treatise. New York (NY, USA): Academic Press; 1964. [Google Scholar]
  • [17].Richard V, Dodson GG, Mauguen M. Human deoxyhaemoglobin-2,3-diphosphoglycerate complex low salt structure at 2.5 Å resolution. J Mol Biol. 1993;233(2):270–274. [DOI] [PubMed] [Google Scholar]
  • [18].Hobish MK, Powers DA. The binding of physiologically significant protons to 2,3-diphosphoglycerate. Biophys Chem. 1983;18(4):407–411. [DOI] [PubMed] [Google Scholar]
  • [19].Bobadilla L, Nino F, Narasimhan G. Predicting and characterizing metal-binding sites using support vector machines. Proc ICBA. 2005;8(1):307–318. [Google Scholar]
  • [20].Ito S, Nakahari T, Yamamoto D. The structural feature surrounding glycated lysine residues in human hemoglobin. Biomed Res. 2011;32(3):217–223. [DOI] [PubMed] [Google Scholar]
  • [21].Higgins PJ, Bunn HF. Kinetic analysis of the non-enzymatic glycosylation of hemoglobin. J Biol Chem. 1981;256(10):5204–5208. [PubMed] [Google Scholar]
  • [22].Lowrey CH, Lyness SJ, Soeldner JS. The effect of hemoglobin ligands on the kinetics of HbA1c formation. J Biol Chem. 1985;260(21):16111–16118. [PubMed] [Google Scholar]
  • [23].Park B, Holman RW, Slade T, et al. A biochemistry question-guided derivation of a potential mechanism for HbA1c formation in diabetes mellitus leading to a data-driven clinical diagnosis. J Chem Ed. 2016;93(4):795–797. [Google Scholar]
  • [24].Gil H, Peña M, Vásquez B, et al. Catalysis by organic phosphates of the glycation of human hemoglobin. J Phys Org Chem. 2002;15(12):820–825. [Google Scholar]
  • [25].Kunika K, Itakura M, Yamashita K. Inorganic phosphate accelerates hemoglobin A1c synthesis. Life Sci. 1989;45(7):623–630. [DOI] [PubMed] [Google Scholar]
  • [26].Smith BA, Mottishaw CR, Hendricks AJ, et al. Potential roles of inorganic phosphate on the progression of initially bound glucopyranose toward the nonenzymatic glycation of human hemoglobin: Mechanistic diversity and impacts on site selectivity. Cogent Biol. 2018;4(1):1–18. doi: 10.1080/23312025.2018.1425196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • [27].Bevington A, Mundy KI, Yates AJP, et al. A study of intracellular orthophosphate concentration in human muscle and erythrocytes by 31P nuclear magnetic resonance spectroscopy and selective chemical assay. Clin Sci. 1986;71(6):729–735. [DOI] [PubMed] [Google Scholar]
  • [28].Gupta RK, Benovic JL, Rose ZB. The determination of free magnesium level in the human red blood cell by 31P NMR. J Biol Chem. 1978;253(17):6172–6176. [PubMed] [Google Scholar]
  • [29].Goldstein DE, Little RR, Lorenz RA, et al. Tests of glycemia in diabetes. Diabetes Care. 1995;18(6):896–909. [DOI] [PubMed] [Google Scholar]
  • [30].De Heer J The principle of Le Chatelier and Braun. J Chem Ed. 1957;34(8):375–380. [Google Scholar]
  • [31].Nakashima K, Hattori Y, Yamazaki K, et al. Immediate elimination of labile Hb A1c with allosteric effectors of hemoglobin. Diabetes. 1990;39(1):17–21. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supp1

Supplementary Figure 1. Impacts of added acid on a mixture of labile and stable Hb A1c. The first section of Figure (a): labile Hb A1c outlines the result of adding excess acid (H-A+) to labile Hb A1c. First, a nearby water molecule must attack as a nucleophile at the electrophilic C double bonded to the N. Then, a base (B that can be 2,3-BPG, water, etc.) abstracts the proton from the now-attached water molecule to form the uncharged carbinolamine species. The carbionolamine is then protonated by an acid (H-A+), which is now a sufficiently reactive species. This is the key step at which added acid promotes the removal of labile Hb A1c, structure 3, by facilitating the protonation of the carbinolamine that then undergoes an intramolecular rearrangement, where one lone pair of electrons on the O forms a double bond with the neighboring C as the bond between the N and the C is broken. The products of this reaction are a ring-opened glucose (structure 2) and the native amino acid residue (either a lysine or the N-terminal valine). Structure 2 can then undergo an intramolecular reaction to form the species shown above, a ring-closed glucopyranose (structure 1), or any of the glucose anomers and tautomers. The newly reformed glucose species can then disassociate entirely from the protein pocket and return to solution, leaving a pocket without any process in NEG. Therefore, addition of acid to labile Hb A1c results in reversion of NEG and does not form AGEs. The second section of Figure (b): stable Hb A1c outlines the result of adding excess acid (H-A+) to structure 6 stable Hb A1c. Two different reactions can occur. The first, colored in dark green and labeled a, involves the deprotonation of an acidic species by the α-nitrogen. The product, an N-protonated Amadori intermediate has no outlet other than to return to structure 6. The second reaction is colored in bright blue and is labeled b. The product, an O-protonated Amadori intermediate has no outlet other than to return to structure 6. It is important to note that there is no reversion to labile Hb A1c or to the ring-opened glucose with the addition of acid. The glucose has no chance to disassociate from the protein, and thus, both reactions have no productive outlet, and can only return to structure 6. Therefore, addition of acid to stable Hb A1c does not affect the concentration of structure 6 or the degree of AGE formation. Taken collectively then, addition of acid will remove labile Hb A1c, structure 3, by pushing the equilibrium towards the formation of detached glucose while the concentration of stable Hb A1c structure 6, remains constant.

RESOURCES